RE:New Press Release - Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023and this is the challenge when pela is used as a rescue or third-line type of therapy.
from the press release:The authors believe that protective immune responses were initiated in these patients but that they may have been too immunocompromised or have insufficient time before disease progression to fully benefit from the pelareorep-based immunotherapy.
when it takes 9 months to "bloom", administering to someone whose immune system is shot or severely wounded doesn't seem to be the correct approach.
getting an approval and then being able to administer "off label" immediately might save a lot more patients.